These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 22401158

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
    Ververs TF, van Dijk A, Vinks SA, Blankestijn PJ, Savelkoul JF, Meulenbelt J, Boereboom FT.
    Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
    Krueger WA, Neeser G, Schuster H, Schroeder TH, Hoffmann E, Heininger A, Dieterich HJ, Forst H, Unertl KE.
    Chemotherapy; 2003 Dec; 49(6):280-6. PubMed ID: 14671427
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
    Kuti JL, Nicolau DP.
    Chemotherapy; 2005 Jul; 51(4):211-6. PubMed ID: 15985760
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
    Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G.
    Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
    Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP.
    Pharmacotherapy; 2003 Aug; 23(8):988-91. PubMed ID: 12921245
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA, Hudson JQ, Hill DM, Swanson JM, Wood GC, Laizure SC, Arnold-Ross A, Hu ZY, Hickerson WL.
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic modeling and dosage adaptation of biapenem in Japanese patients during continuous venovenous hemodiafiltration.
    Ikawa K, Morikawa N, Ikeda K, Suyama H.
    J Infect Chemother; 2008 Feb; 14(1):35-9. PubMed ID: 18297447
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y, Kobayashi Y.
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
    Banyai M, Thalhammer F, El-Menyawi I, Heinz G, Traunmüller F, Siostrzonek P.
    Clin Pharmacol Ther; 2000 Apr; 67(4):368-72. PubMed ID: 10801245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.